Achieving a malaria-free world presents exciting scientific challenges as well as
overwhelming health, equity, and economic benefits. WHO and countries are setting …

Purpose The pathophysiology, diagnosis, and medication-use implications of glucose-6-
phosphate dehydrogenase (G6PD) deficiency, the most common enzyme deficiency in …

Abstract Background Tafenoquine, an 8-aminoquinoline, is now indicated for causal
prophylaxis against all human malarias and as radical curative (anti-relapse) treatment …

Low glucose-6-phosphate dehydrogenase enzyme (G6PD) activity is a key determinant of
drug-induced haemolysis. More than 230 clinically relevant genetic variants have been …

Abstract Background Quantitative measurement of Glucose-6-Phosphate Dehydrogenase
(G6PD) enzyme activity is critical to decide on appropriate treatment and provision of radical …

Background To reduce the risk of drug-induced haemolysis, all patients should be tested for
glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing …

Since the turn of the century, a remarkable expansion has been achieved in the range and
effectiveness of products and strategies available to prevent, treat, and control malaria …

Background Glucose-6-Phosphate dehydrogenase (G6PD) deficiency is the most common
enzymopathy worldwide, no reliable bedside diagnostic tests to quantify G6PD activity exist …

Background The introduction of novel short course treatment regimens for the radical cure of
Plasmodium vivax requires reliable point-of-care diagnosis that can identify glucose-6 …

Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of
severe haemolysis following the administration of 8-aminoquinoline compounds …